APA (7th ed.) Citation

TA, O., & HJ, B. (2026). Long-term outcomes with adjuvant CDK4/6 inhibitors: Who benefits most? Annals of oncology : official journal of the European Society for Medical Oncology, 37(2), 133. https://doi.org/10.1016/j.annonc.2025.10.012

Chicago Style (17th ed.) Citation

TA, O'Meara, and Burstein HJ. "Long-term Outcomes with Adjuvant CDK4/6 Inhibitors: Who Benefits Most?" Annals of Oncology : Official Journal of the European Society for Medical Oncology 37, no. 2 (2026): 133. https://doi.org/10.1016/j.annonc.2025.10.012.

MLA (9th ed.) Citation

TA, O'Meara, and Burstein HJ. "Long-term Outcomes with Adjuvant CDK4/6 Inhibitors: Who Benefits Most?" Annals of Oncology : Official Journal of the European Society for Medical Oncology, vol. 37, no. 2, 2026, p. 133, https://doi.org/10.1016/j.annonc.2025.10.012.